Seeking Alpha

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Business Insider

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension ...

MONROE TOWNSHIP, N.J., July 15, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms (see Indications and Important Safety ...
Seeking Alpha

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...
Morningstar

Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors

Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney ...
Business Wire

International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums announce partnership to advance IV training for sonographers

CHICAGO--(BUSINESS WIRE)--The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) today announced an educational partnership to help train sonographers to perform ...